Physician Sentiment on TECVAYLI®

“Prior to starting teclistamab, baseline BCMA expression & immune characteristics were unaffected by prior anti-BCMA treatment.” 🤯 Fascinating @BloodJournal #MMsm results of MajesTEC-1 in BCMA-exposed pts. Congrats Touzeau @DoctorAKrishnan @szusmani @NBahlis @AlGarfall et al!

See full MajesTEC-3 conference coverage & trial data →

@RahulBanerjeeMD

Full physician voice list (3)

Physician	Comment (verbatim)	Sentiment	Impressions
Ben Derman @bdermanmd	Intriguing data from MajesTEC-7 (Tec-Dara-R) safety-run in. First off: Dara-Rd lead in before adding teclistamab led to high rates of grade 3 CRS and neutropenia. So Tec and dara first --> then add len after. #ASCO24 #mmsm	Neutral	4,230
Rahul Banerjee, MD, FACP @RahulBanerjeeMD	“Prior to starting teclistamab, baseline BCMA expression & immune characteristics were unaffected by prior anti-BCMA treatment.” 🤯 Fascinating @BloodJournal #MMsm results of MajesTEC-1 in BCMA-exposed pts. Congrats Touzeau @DoctorAKrishna…	Positive	2,964
Samer Al Hadidi, MD,MS,FACP @HadidiSamer	#mmsm #ASCO24 MajesTEC-1 - teclistamab ➡️ https://t.co/AGYV7BcngN ✅Median follow up:2.5 years ✅Median DOR: 2 years ✅Median PFS: ~ 1 year ✅Median OS: ~ 2 years 🛑>half pts with G3/4 infections, 13% (22/165) deaths related to infection (most…	Neutral	2,164

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Trial 2 · NCT05083169

What do oncologists think of the MajesTEC-3 trial (TECVAYLI®)?

MajesTEC-3 — Relapsed/refractory multiple myeloma after >=1 prior line (teclistamab + SC daratumumab, 'Tec-Dara')

FDA APPROVED · Mar 2026 · with daratumumabFDA-approved March 5, 2026 in combination with daratumumab and hyaluronidase-fihj (subcutaneous daratumumab) for relapsed or refractory multiple myeloma after at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent (based on MajesTEC-3).

Physicians are broadly favorable, with real nuance on MajesTEC-3: 42% of 31 verified physician voices positive, 6% nuanced (praising the result while flagging a caveat), 52% neutral, 0% critical.

42%

52%

Positive 42% Nuanced 6% Neutral 52% Critical 0%

Denominator: 31 distinct verified physician voices across 145 oncologist posts, 2025-11-24 to 2026-05-29. Sponsor: Janssen Research & Development (Johnson & Johnson)

Primary sources: ClinicalTrials.gov · NCT05083169 · FDA — MajesTEC-3 combination approval (Mar 2026)

FDA approval (Mar 5, 2026): teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj for relapsed or refractory multiple myeloma after at least one prior line of therapy (based on MajesTEC-3, NCT05083169).

Physician voices — verbatim

Unprecedented. #ASH25 Tec-Dara in relapsed myeloma. @mvmateos

Vincent Rajkumar

@VincentRK

Vincent this would be a great Monday meeting discussion. Here are my points of confusion 1) Ciltacel 2nd line in Dara naive makes me pause. here is the OS curve for 2nd line patients with Ciltacel (source https://t.co/WiL1IPdtAH). Tec-Dara would obviously be way safer but... 1/ https://t.co/9A8eLMmw9e

Taxiarchis Kourelis

@Taxkourel

Full physician voice list (31)

Physician	Comment (verbatim)	Sentiment	Impressions
Vincent Rajkumar @VincentRK	Unprecedented. #ASH25 Tec-Dara in relapsed myeloma. @mvmateos	Positive	62,574
Samer Al Hadidi, MD,MS,FACP @HadidiSamer	#ASH25 #mmsm @ASH_hematology Treatment Refinement in Multiple Myeloma @SLentzsch Reasons why CAR-T should be positioned before BsAbs	Neutral	15,989
Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD	Finally I found the 10th abstract for #ASH25 🔥🔥🔥 Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of DPd/DVd in Pts with RRMM: majestec-3 1/ 🔥 Practice-changing data in RRMM! MajesTEC-3 is the first ph…	Positive	14,700
Luciano J Costa @End_myeloma	Implications are many: Off-the-shelf, highly active, outpatient-based, community-accessible, T-cell redirecting therapy. Steroid free with a convenient schedule. It will force us to reappraise options in 1-3 LOT.	Neutral	13,802
Murali Janakiram @JanakiramMurali	Wow its happening.... Cure / long term remission in early relapse MM Dara-Tec vs DPD/DVD -PFS @ 36 mo (HR, 0.17; 95% CI, 0.12-0.23)-83.4% vs 29.7% -OS (HR, 0.46; 95% CI, 0.32-0.65)-83.3% and 65.0% Any grade infections- 96.5% and 84.1% of Te…	Neutral	11,474
Rahul Banerjee, MD, FACP @RahulBanerjeeMD	#ASHkudos to @SLentzsch This is the nicest and most succinct explanation I’ve seen for CAR-T before bsAbs in myeloma 👏 And I agree! Even once MajesTEC-3 approved based on #ASH25 results, please make sure #MMsm pts hear about BCMA CAR-T a…	Positive	11,053
Raj Chakraborty @rajshekharucms	Game-Changer! The plateau is hard to beat. With universal IVIG prophylaxis, these results could be event better by averting the early infection-related deaths, which would have potentially pushed the 3-year PFS beyond 90%! Now awaiting Maje…	Positive	9,948
Taxiarchis Kourelis @Taxkourel	Vincent this would be a great Monday meeting discussion. Here are my points of confusion 1) Ciltacel 2nd line in Dara naive makes me pause. here is the OS curve for 2nd line patients with Ciltacel (source https://t.co/WiL1IPdtAH). Tec-Dara …	Nuanced	9,868
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1	#ASH25RF #mmsm	Neutral	5,487
nizar jacques bahlis @NBahlis	Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma \| New England Journal of Medicine. A new dawn in myeloma therapy. Cure in sight! #ASH2025 ⁦@NEJM⁩	Neutral	5,180
Henry C Fung\| MM, lymphoma, leukemia & CART @henrychihangfu1	It’s MajesTEC-1,2,3,4,5,7,9… but I call it #MagicTec ✨🧬 An easier way to remember the journey: 🔹 Magic 1 Advanced / heavily pretreated disease 🔹 Magic 3 1st+ relapse, non-Dara refractory (teclistamab + Dara moving earlier) 🔹 Magic…	Nuanced	4,446
M. Hossein Kazemi @hkazemi83	How would you think through this regiment vs cilta cel for eligible patients?	Neutral	4,388
Benlazar S M A @smbenlazar	TECLISTAMAB PLUS DARATUMUMAB (TEC-DARA) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF MAJESTEC-3 BASED ON CYTOGENETIC AND FUNCTIONAL RISK https://t.co/MCb33znS4i #mmsm #EHA26	Neutral	4,300
Mike Thompson, MD, PhD, FASCO @mtmdphd	Ph3 RCT teclistamab + daratumumab vs investigator’s choice of dara-dex + either pomalidomide or bortezomib (DPd/DVd) in Pts w/RRMM: Results of MajesTEC-3 [Dec 9, 2025] @mvmateos et al. @End_myeloma #ASH25 LBA6 https://t.co/05T5SpqCpg #NCT05…	Neutral	4,143
Ben Derman @bdermanmd	The main change for this cycle: "Ciltacabtagene autoleucel or the combination of teclistamab and daratumumab are preferred options at first relapse in eligible patients who have not previously received B-cell maturation antigen (BCMA) direc…	Neutral	3,847
Hamza Hashmi @hhashmi87	MajesTEC-3 was one of the first trials I enrolled #RRMM patients on as a junior investigator and saw some truly profound and deep responses in high-risk patients. Approval of Dara/Tec will be a big win for #myeloma patients.	Positive	3,796
Andrew Yee, MD @andrew02114	Looking forward to seeing the data on teclistamab and daratumumab in MajesTEC-3 presented at #ASH25 by @mvmateos @End_myeloma . The study population of 1-3 prior lines, prior PI and IMiD, and control arm of dara pom dex or dara Vel dex is…	Neutral	3,745
Andrew M. Evens, DO, MBA, MSc @DrAEvens	👏👏 Super kudos to Dr @mvmateos & Dr @End_myeloma and all co-authors on this pivotal study and these outstanding results (via @ASH_hematology)! #ASH25 #ASH2025 #ASHKudos	Positive	2,932
Al Garfall @AlGarfall	Ongoing studies will directly address early-line Tec in dara-ref pts. Until then, we can accept the big-picture finding that second-line bispecifics offer an exceptionally effective option for those who don’t want cilta-cel risks or otherwi…	Positive	2,290
Jim Omel @IMFjimMYELOMA	Good reasoning, but Late Breaking Abstract #ASH25 will show amazing results with Tec/Dara. Community based. Available immediately. Very Effective.	Positive	1,532
Hira Mian @HiraSMian	100% agree and further supports maybe not using an anti-CD38 in everyone in first line till progression :)	Neutral	1,474
Mehdi Hamadani, MD @MediHumdani	Congrats Luciano, with community adoption start of the end of CAR for all in second line?	Positive	1,054
Santhosh Ambika @RenoHemonc	And avoid Belantamab REMS headache . Rx choices on progression will be interesting.	Neutral	502
gilberto lopes @GlopesMd	Teclistamab + Daratumumab Is a Potential Cost-Effective Option in Relapsed/Refractory Multiple Myeloma https://t.co/uJkVgoYEkU #ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @…	Neutral	441
Jose Sandoval S, MD FACP 🇨🇴🇨🇴 @HemSandoval	Very interesting and powerful results. Question: Why was dara/carfilzomib/dex not included as part of the control options? How can I chose between DKd and this option?	Positive	228
Amer Zeidan MBBS,MHS ‏عامر زيدان @Dr_AmerZeidan	Impressive. How many people received dara or tec second line?	Positive	222
Irene Ghobrial @IrenemGhobrial	Congrats! Keep improving until we have a cure.	Positive	218
Jim Cavet🍉🆘🇵🇸🕊️ @CavetJim	Only truly #transformative in #MM #sequencing if #RCT w/. #crossover access 2 highly-active #BCMA #BiTE at #PD (given these agents clearly #paradigmshift in #myeloma)	Positive	202
Ankit kansagra @kansagramd	One framing point: don't line MajesTEC-9 up against MajesTEC-3. Different experiment — monotherapy vs a tec+DARA doublet, CD38-exposed vs CD38-refractory-EXCLUDED, 17 vs 34 mo follow-up. The matched comparator is MonumenTAL-6 (talquetamab,…	Neutral	189
Marc Braunstein, MD, PhD, FACP @docbraunstein	Looking forward to your thoughts. Questions I have heard are (1) How does this apply in dara-exposed/refractory (only 5% exposed in Tec-3), (2) where does CART fit in now in 2L+ before/after, and (3) Tec+Tal vs Tec+Dara (@mvmateos noted bot…	Neutral	144
Gurbakhash Kaur @GKaurMD	As bsAB start to get widely implemented with prophy toci, & outpt ramp ups, CAR-T referrals will happen after pts refractory to bsAB! Next gen CAR-T in development should generate that data esp bc they will Have late line approval. #as…	Neutral	87

See full MajesTEC-3 conference coverage & trial data →

Trial 3 · NCT05572515

What do oncologists think of the MajesTEC-9 trial (TECVAYLI®)?

MajesTEC-9 — Relapsed/refractory multiple myeloma after 1-3 prior lines (teclistamab monotherapy vs PVd or Kd) — INVESTIGATIONAL earlier-line

INVESTIGATIONAL · earlier-line monotherapyInvestigational in this setting. Teclistamab monotherapy is FDA-approved only for relapsed or refractory multiple myeloma after at least four prior lines of therapy; MajesTEC-9 studies teclistamab monotherapy earlier — after one to three prior lines — where it is not FDA-approved.

Physicians are genuinely mixed on MajesTEC-9: 15% of 20 verified physician voices positive, 25% nuanced (praising the result while flagging a caveat), 60% neutral, 0% critical.

15%

25%

60%

Positive 15% Nuanced 25% Neutral 60% Critical 0%

Denominator: 20 distinct verified physician voices across 99 oncologist posts, 2026-01-14 to 2026-06-04. Sponsor: Janssen Research & Development (Johnson & Johnson)

See full MajesTEC-9 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT05572515

Physician voices — verbatim

So exciting for our pts, bispecifics are the new SOC in early relapse.

Hira Mian

@HiraSMian

MagnetisMM-5 press release - elra outperformed DPd in myeloma with 1+ prior line! Obviously all eyes will be on this vs MajesTEC-3 (and more pertinently, MajesTEC-9)… … but this confirms that the heyday of Dara-Pd and Isa-Pd at first relapse is rapidly coming to an end 👏

See full MajesTEC-9 conference coverage & trial data →

@rahulbanerjeemd

Full physician voice list (20)

Physician	Comment (verbatim)	Sentiment	Impressions
Vincent Rajkumar @VincentRK	Just out: Majestic Majestec-9 results. #ASCO26 @NEJM Single agent teclistamab beats standard triplet in relapsed myeloma. https://t.co/2TeFjBuZSv @DrOlaLandgren @thanosdimop	Neutral	16,731
Oncology Brothers @OncBrothers	Day 1 #ASCO26 highlights: 1. #CROWN (update): ALK+ NSCLC 2. #OptiTROPLung05: SacTMT/IO NSCLC 3. #WuKONG28: EGFR 20 NSCLC 4. #EV302 (update): EV-Pembro mUC 5. #MajesTEC9: Teclistamab in RRMM 6. #SUCCESSOR2: Mezigdomide in RRMM #…	Neutral	15,989
Ben Derman @bdermanmd	We now have release of SUCCESSOR-2 data! Mezi + weekly Kd vs twice weekly Kd - 85% anti cd38 refractory - mPFS 18 vs 8 months (control arm did the same as MajesTEC-9) My take: 18 months is nothing to scoff at, and compares favorably with K…	Neutral	14,787
Samer Al Hadidi, MD,MS,FACP @hadidisamer	#mmsm #ASCO26 MajesTEC-9 ➡️Tec vs. PVd/Kd (1-3 prior lines of therapy) ➡️Len refractory: 80%; anti-CD38 refractory: 85% ➡️median F/U ~1.5 yrs ➡️18-mo PFS rate: 70% vs 27% ➡️improved OS with Tec vs PVd/Kd (HR: 0.60), even with >2/3 of pts g…	Neutral	12,729
Raj Chakraborty @rajshekharucms	1. MajesTEC-9 [Tec vs PVd/Kd]: Single-agent Tec decimated PVd/Kd in a population that was 80% anti-CD38-refrcatory and 85% Len-refractory, with a PFS HR of 0.29 and OS HR of 0.6. While the trial should have ideally allowed crossover to Te…	Neutral	7,472
Mohamad Mohty @Mohty_EBMT	MAJESTEC-9 trial at #ASCO26 : the message was strikingly simple: a couple of curves summarized it all. At the end, curves speak louder than words. @TheIACH @COMyCongress	Neutral	6,323
Rahul Banerjee, MD, FACP @rahulbanerjeemd	MagnetisMM-5 press release - elra outperformed DPd in myeloma with 1+ prior line! Obviously all eyes will be on this vs MajesTEC-3 (and more pertinently, MajesTEC-9)… … but this confirms that the heyday of Dara-Pd and Isa-Pd at first rela…	Nuanced	6,153
Dr Rishabh Jain @DrRishabhOnco	Concomitant publication in @NEJM #ASCO26 BCMA bispecific moves earlier in myeloma. MajesTEC-9 \| NEJM 2026 Teclistamab monotherapy vs PVd/Kd in RRMM after 1-3 prior lines, all exposed to anti-CD38 + lenalidomide. 🧬 18-mo PFS 69.8% vs 26.…	Neutral	5,754
Henry C Fung\| MM, lymphoma, leukemia & CART @henrychihangfu1	MajesTec - 9 & MajecTec - 3 & Cartitude - 4 - My interpretations. IMO: the real question is no longer Tec vs CAR-T. The real question is: which patient should receive which immunotherapy, and when? MajesTEC-9, CARTITUDE-4, and CARTITUDE…	Nuanced	5,371
Dr. Jeffrey Zonder @Amyloid_Planet	majesTEC-9 results posted: Tec crushed PVd/Kd for #myeloma after 1-3 prior LOT. Results relevant for US practice, as 85% of pts were anti-CD38 refractory. 18m PFS: 70% (vs 30% for pVd/Kd), w OS benefit too (HR 0.60).	Neutral	2,903
Luciano J Costa @end_myeloma	Incidentally, the exact same arguments can be made about Kd/PVd in control of MajesTEC-9. @JJ_IMMedAffairs	Neutral	2,137
Ankit kansagra @kansagramd	MajesTEC-9 just landed in NEJM — the first phase 3 to run a BCMA bispecific as a SINGLE agent at first-or-later relapse, in patients already exposed to anti-CD38 + lenalidomide. The topline: a 71% cut in progression or death. But the full …	Nuanced	1,612
Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD	1/ 🧵 A Dominant Victory for BCMA: Teclistamab Scores Big in MajesTEC-9 from #ASCO26 Teclistamab moves earlier in RRMM! MajesTEC-9 evaluated teclistamab monotherapy vs PVd/Kd in patients with MM after 1–3 prior lines, all exposed to lenal…	Neutral	951
Yan Leyfman, MD @YLeyfman	For years, BCMA-directed therapies have delivered remarkable results in heavily pretreated multiple myeloma. The question has been: what happens if we move them earlier? The phase 3 MajesTEC-9 trial provides a compelling answer. Patients …	Positive	695
MV Chandrakanth @ChandrakanthMv	ASCO 2026 Update — MajesTEC-9 • Teclistamab significantly improved PFS vs PVd/Kd in early RRMM • Deep responses: ≥CR 65.9% vs 16.8% • Benefit seen in a heavily refractory population • OS improvement observed despite later BCMA-directed the…	Neutral	594
RobertoMina_MD @RobertoMinaMD	MM patients relapsed/refractory to daratumumab-lenalidomide are a clinical challenge. Tec-9 reinforces the role of BCMA-targeting therapies in earlier lines and that of Tec as a new SoC in this setting.	Neutral	442
Hira Mian @HiraSMian	So exciting for our pts, bispecifics are the new SOC in early relapse.	Positive	369
Hamza Hashmi @hhashmi87	Great results. It’s likely all high risk patients have progressed by now, Given follow up of 18 months, we should wait to see if slope plateaus out. The curve plateaued with Tec-3 at 6 months with no relapses beyond 12m.	Positive	268
John Herrmann, PhD @ablT315I	Solid! CAR‑Ts still offers long-tail “plateau” remissions in some — but, Tecvayli will very likely shifts most patients to TCEs first. MajesTEC‑9 raises the floor for all next-gen CAR-T including in-vivo	Nuanced	109
Noah Lindenberg, MD Oncologist-Hematologist @nlindenberg	Tec beat a weak control arm, at a real toxicity cost. About 15% weren't truly CD38 refractory but still did not receive additional Dara. The OS signal is likely real but inflated by weak control arm. We should have learned this lesson from…	Nuanced	39

Trial 4 · NCT05695508

What do oncologists think of the MajesTEC-5 trial (TECVAYLI®)?

MajesTEC-5 — Transplant-eligible newly diagnosed multiple myeloma — teclistamab-based induction (Tec-DR +/- bortezomib) — INVESTIGATIONAL

INVESTIGATIONAL · frontline inductionInvestigational. MajesTEC-5 (GMMG-HD10/DSMM-XX) studies teclistamab-based induction regimens (with daratumumab and lenalidomide, with or without bortezomib) in transplant-eligible newly diagnosed multiple myeloma; teclistamab is not FDA-approved in the frontline setting.

Physicians are broadly favorable, with real nuance on MajesTEC-5: 46% of 15 verified physician voices positive, 7% nuanced (praising the result while flagging a caveat), 40% neutral, 7% critical.

46%

40%

Positive 46% Nuanced 7% Neutral 40% Critical 7%

Denominator: 15 distinct verified physician voices across 42 oncologist posts, 2024-12-08 to 2025-09-19. Sponsor: GMMG / DSMM (academic) with Janssen (Johnson & Johnson)

See full MajesTEC-5 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT05695508

Physician voices — verbatim

#IMS25 In my mind, this will be the slayer of ASCT more than any other #MMsm regimen... Excellent Tec-DVR & Tec-DR data [1x weekly Velcade & lots of IVIG 👏] in NDMM from MajesTEC-5 @RaabMarc 100% ORR, 100% MRD neg across the board. This is what we hope for with induction!

@RahulBanerjeeMD

This is the start of a revolution. Still lots of work to do but the future of myeloma therapy is clear to see and it couldn’t be more exciting.

Peter Forsberg MD

@ForsbergMD

Representative critical voice

Updates from MajesTEC-5: Continue to see unprecedented mrd negativity rates after just 6 cycles of teclistamab + Dara-R and +\- bortezomib. Pretty clear that bortezomib thus far not offering benefit. Is transplant really needed either? Infection rates a bit concerning with short

Ben Derman

@bdermanmd

Full physician voice list (15)

Physician	Comment (verbatim)	Sentiment	Impressions
Rahul Banerjee, MD, FACP @RahulBanerjeeMD	#IMS25 In my mind, this will be the slayer of ASCT more than any other #MMsm regimen... Excellent Tec-DVR & Tec-DR data [1x weekly Velcade & lots of IVIG 👏] in NDMM from MajesTEC-5 @RaabMarc 100% ORR, 100% MRD neg across the board. This …	Positive	9,108
Thilo J. Zander @ThiloZander	‼️100% MRD Negativity after 6 cycles of Teclistamab-based induction in NDMM is something we will remember @RaabMarc #myeloma #IMS2025	Neutral	4,273
Ben Derman @bdermanmd	Updates from MajesTEC-5: Continue to see unprecedented mrd negativity rates after just 6 cycles of teclistamab + Dara-R and +\- bortezomib. Pretty clear that bortezomib thus far not offering benefit. Is transplant really needed either? Infe…	Negative	3,690
Raj Chakraborty @rajshekharucms	Exciting data from MajesTEC-5 by Dr. Raab. Tec-Dara based induction leading to ~100% MRD-negativity rate by NGS at 10^-6 post Cycle#6. At ~7 mo f/u risk of Grade 3 or higher infection ~37% (no deaths from infection yet). My thoughts: Is AS…	Positive	3,178
Hamza Hashmi @hhashmi87	#IMS25 MajesTEC_5: Tec+DaraRV for TE NDMM: N=50, 100% MRD neg by NGS 10-6 after C6, all pts collected stem cells G3 infection 33%, hypogamma 90% MRD neg much higher than SOC DRVd Id this Rx for ‘Time limited therapy’,? Role of ASCT with s…	Neutral	3,124
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1	MjesTEC-5 ORR 100%, 95-100 CR, MRD- 100% including 10-6. #IMS2025 #mmsm	Neutral	2,678
Luciano J Costa @End_myeloma	Is this a year 2000, STI571 moment?	Neutral	1,084
Marc-A. Bärtsch @marc_a_baertsch	The overflow rooms were overflowing! Important contributions from German study groups GMMG and DSMM in NDMM: impressive 100% MRD negativity with Teclistamab based regimens in HD10 presented by @RaabMarc and significant PFS benefit with Isa-…	Positive	809
Gareth Morgan @DrGarethMorgan1	These combinations are safe and hugely effective and are going to get most patients to have no detectable disease great work from my German friends	Positive	631
Peter Forsberg MD @ForsbergMD	This is the start of a revolution. Still lots of work to do but the future of myeloma therapy is clear to see and it couldn’t be more exciting.	Nuanced	257
Samer Al Hadidi, MD,MS,FACP @HadidiSamer	#ASH24 #mmsm @ASH_hematology Oral myeloma: GMMG-HD10/DSMM-XX (MajesTEC-5) Responses are high and deep with ongoing follow up 100% MRD -ve and sCR in Arm A and other arms follow up ongoing (very nice to see such responses) Vaccines were r…	Neutral	184
Murali Janakiram @JanakiramMurali	This is encouraging Rahul no issues with collection	Positive	139
Bhuvan Kishore @bloodmed	These are amazing results. Probably sets the bar quite high if MRD 💯 is to be beaten. The only way forward from here is deescalation or deferred ASCT. Sustained MRD hopefully will be as good.	Positive	139
Becky Bosley @MidAtlanticMSG	Abstract #493 Phase 2 study of Tec-based induction in pts with TE-NDMM: Results from the MajesTEC-5 trial #IMFASH24 #ASH24 Exciting early data! 100% MRD negativity so far, hoping for sustained MRD negativity!	Positive	69
Santhosh Ambika @RenoHemonc	Shouldn’t do stem cell toxic ASCT in MRD-, may impede future CaR-T options …	Neutral	19

See full MajesTEC-5 conference coverage & trial data →

Trial 5 · NCT05243797

What do oncologists think of the MajesTEC-4 trial (TECVAYLI®)?

MajesTEC-4 — Maintenance after autologous stem-cell transplant in newly diagnosed myeloma (teclistamab +/- lenalidomide) — INVESTIGATIONAL

INVESTIGATIONAL · post-ASCT maintenanceInvestigational. MajesTEC-4 studies teclistamab (with or without lenalidomide) as maintenance after autologous stem-cell transplant in newly diagnosed multiple myeloma; teclistamab is not FDA-approved as frontline maintenance.

Physicians are broadly favorable, with real nuance on MajesTEC-4: 22% of 14 verified physician voices positive, 14% nuanced (praising the result while flagging a caveat), 64% neutral, 0% critical.

22%

14%

64%

Positive 22% Nuanced 14% Neutral 64% Critical 0%

Denominator: 14 distinct verified physician voices across 38 oncologist posts, 2024-11-10 to 2026-06-16. Sponsor: European Myeloma Network with Janssen (Johnson & Johnson)

See full MajesTEC-4 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT05243797

Physician voices — verbatim

#mmsm #EHA26 MajesTEC-4 Amazing data ✅ ≥CR was achieved in nearly 100% of patients across all 3 cohorts (100%, 96.9%, and 96.7%), up from roughly 41–60% post-ASCT ✅ Median PFS was not reached in any cohort. Estimated 18- and 24-month PFS rates were 94–97% Only 3 progression

Samer Al Hadidi, MD,MS,FACP

@HadidiSamer

#EHA2026 #nielsvandedonk MajesTEC-4 SRI data At first glance, shocking that tec (bsAb) dose intensity so much higher than len dose intensity (~90% vs ~50%) 🤯 But honestly not surprising - len maintenance can be tough! Q4W tec with optimal supportive care quite maintainable.

See full MajesTEC-4 conference coverage & trial data →

@RahulBanerjeeMD

Full physician voice list (14)

Physician	Comment (verbatim)	Sentiment	Impressions
Henry C Fung\| MM, lymphoma, leukemia & CART @HenrychihangFu1	MajesTEC-4 was the most fascinating study reported at EHA 2026 for me. Not because 100% MRD negativity (10⁻⁵) was achieved. What truly caught my attention was the magnitude and speed of CR/sCR conversion. After ASCT, CR/sCR rates were ap…	Neutral	5,752
Samer Al Hadidi, MD,MS,FACP @HadidiSamer	#mmsm #EHA26 MajesTEC-4 Amazing data ✅ ≥CR was achieved in nearly 100% of patients across all 3 cohorts (100%, 96.9%, and 96.7%), up from roughly 41–60% post-ASCT ✅ Median PFS was not reached in any cohort. Estimated 18- and 24-month PFS r…	Positive	3,795
Eddie Cliff @Eddie_Cliff	I felt the same - amongst the myeloma abstracts, there were many exciting BsAb studies, and the MajesTEC-4 data, tho preliminary, are incredibly exciting @HadidiSamer	Positive	3,569
Hamza Hashmi @hhashmi87	I like that Teclistamab was used as maintenance post ASCT for pt#2. With uncontrolled chemo refractory EMD, going straight to ASCT often leads to relapse <60 days post ASCT. For EMD with primary ref disease, I do not think Len, D+Len lead t…	Neutral	2,905
Rahul Banerjee, MD, FACP @RahulBanerjeeMD	#EHA2026 #nielsvandedonk MajesTEC-4 SRI data At first glance, shocking that tec (bsAb) dose intensity so much higher than len dose intensity (~90% vs ~50%) 🤯 But honestly not surprising - len maintenance can be tough! Q4W tec with optima…	Nuanced	1,976
Ankit kansagra @kansagraMD	MajesTEC-4: Trial using Tec vs Tec+Len in maintenance post ASCT ! This is early, but the P3 trial of BCMA bispecifics is going to be a huge change in how we manage NDMM. Globally ~180K NDMM are diagnosed, and about ~30-40% are potential…	Nuanced	1,814
Hira Mian @HiraSMian	And this translates to beyond transplant patients, short duration fixed BsAb with proph toci and proph IVIG are likely the most tolerable treatment for older adults.	Neutral	837
Luciano J Costa @End_myeloma	5- MajesTEC-4, Less is more with teclistamab in low burden settings.	Neutral	539
Elias K. Mai MD @EliasKarlMai	#ASH24 #mmsm Anti-BCMA bispecifics arriving in firstline! Curious to see the follow up! @EMN_EuMMnet	Neutral	401
Ben Derman @bdermanmd	Tec-Len safety run in as post-ASCT maintenance #ASH24 #mmsm #mmMRD - Convenient dosing schedule - Nearly everyone got significant neutropenia (94% G3+) - CRS rates are lower overall in this low-disease burden setting (40-50%)	Neutral	387
Mike Thompson, MD, PhD, FASCO @mtmdphd	Ph3 Teclistamab (Tec) + Lenalidomide (R) and Tec Alone vs R Alone in NDMM As Maintenance Tx Following ASCT: Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial [Dec 8, 2024] Zamagni et al. #ASH24 Abst 494 https://t.co/ex2Nv2jVXc #mm…	Neutral	349
Beth Faiman PhD @Bethfaiman	I agree - impressive and rapid #MRD negative rates!! #ASH24	Positive	345
Rakesh Popat @DrRakeshPopat	Majestec 4 - safety lead in for Tec or Tec Len maintenance post ASCT. High MRD conversion rates. Key is going to be balancing the toxicity profile with ongoing treatment. #ASH24 mmsm	Neutral	101
Becky Bosley @MidAtlanticMSG	Abstract #494 Phase 3 study of Tec in combo w/ Len and Tec alone vs Len alone in NDMM as maint after ASCT: SRI results from the MajesTEC-4 / EMN30 trial #IMFASH24 #ASH24 We love the possibility of a fixed duration of maintenance!	Neutral	49

Trial 6 · NCT05552222

What do oncologists think of the MajesTEC-7 trial (TECVAYLI®)?

MajesTEC-7 — Frontline transplant-ineligible/not-intended newly diagnosed myeloma (Tec-DR vs DRd) — INVESTIGATIONAL

INVESTIGATIONAL · frontline transplant-ineligibleInvestigational. MajesTEC-7 is a Phase 3 study of teclistamab plus daratumumab and lenalidomide (Tec-DR) versus daratumumab, lenalidomide, and dexamethasone (DRd) in newly diagnosed multiple myeloma patients ineligible for or not intended for autologous stem-cell transplant; teclistamab is not FDA-approved in the frontline setting.

Physicians are genuinely mixed on MajesTEC-7: 0% of 2 verified physician voices positive, 50% nuanced (praising the result while flagging a caveat), 50% neutral, 0% critical.

50%

Positive 0% Nuanced 50% Neutral 50% Critical 0%

Denominator: 2 distinct verified physician voices across 2 oncologist posts, 2024-12-06 to 2025-02-07. Sponsor: Janssen Research & Development (Johnson & Johnson)

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT05552222

Physician voices — verbatim